Vigil Demonstrates Significant Survival Benefit in cTMB-H/HRP Ovarian Cancer Patients; Ph 2b VITAL Trial Analysis Published in JCO – Precision Oncology
John Nemunaitis, MD, Gradalis’ Chief Scientific Officer and co-founder stated: “Frontline ovarian cancer treatment protocols involving bevacizumab, PARP inhibitors and PD-1/PD-L1 inhibitors have failed to improve overall survival in patients with HRP tumors. To determine mechanistic mutation signatures associated with OS advantage, we conducted blinded post-hoc analyses of the 91 patients treated in the VITAL trial. Based on these data, we hypothesized that patients with an HRP profile and high clonal tumor mutation burden might achieve greater response when undergoing maintenance therapy with Vigil. Results published today validate our hypothesis demonstrating that Vigil delivered a median OS of nearly six years compared to less than two years with placebo. With FDA RMAT Fast Track designation, we are positioned to accelerate development and bring this innovative therapy to patients sooner.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines